Drug intelligence / Profile preview

Dieda Hongyao Tablets

Development stage: Unknown
Lead developer: Wuhan United Pharmacy
Administration: Oral

Overview

Dieda Hongyao Tablets (跌打红药片) is an approved traditional Chinese medicine (TCM) developed and manufactured by Wuhan United Pharmacy under the brand name Tongzhi (同治). The formulation consists of several traditional Chinese medicinal herbs, including Notoginseng Radix et Rhizoma (三七), Carthami Flos (红花), Angelicae Sinensis Radix (当归), Chuanxiong Rhizoma (川芎), Angelicae Dahuricae Radix (白芷), and Eupolyphaga Steleophaga (土鳖虫). It is indicated for promoting blood circulation, resolving blood stasis, relieving pain, and promoting tissue regeneration, making it effective for traumatic injuries, swelling, pain from blood stasis, and rheumatic numbness.

Brand names: TongzhiTongzhi Dieda Hongyao Tablets同治同治跌打红药片
Other names: Dieda Hongyao Pian跌打红药片

Beyond the preview

Go deeper on Dieda Hongyao Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dieda Hongyao Tablets.

Explore the full profile